SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

PHVS

Pharvaris N.V.
BULLISH
Impact 7/10
Horizonweeks Processed4d 16h ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Watch for NDA/MAA submissions for deucrictibant XR prophylaxis; the company already has an NDA/MAA under review for the on-demand IR formulation. Regulatory decisions and potential commercial launch timeline are the next catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

deucrictibant

◆ Mixed Named in this press release
Impact
Phase
Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to market
IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
Next catalyst
None dated

What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$33.83
T+0 close · Nov 12, 2026 · via day close
Latest settled
−1.39%
T+1 · $33.36
Vs SPY
−1.03%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $33.83entry
  2. T+1 · 4d ago −1.39%α −1.03% · $33.36
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris presented positive Phase 3 CHAPTER-3 data at ACAAI 2026, showing deucrictibant XR reduced HAE attack rate by 83% vs placebo (p<0.0001) across all HAE types, with 45% of patients attack-free over 24 weeks. The drug was generally well tolerated with no treatment-related serious adverse events. This is a late-stage biotech with a $2.4B market cap, and the data supports its potential as an oral prophylactic therapy for HAE.

Key Facts

  • Phase 3 CHAPTER-3 met primary and all secondary efficacy endpoints with statistical significance
  • Deucrictibant XR reduced monthly HAE attack rate by 83% vs placebo across all HAE types (p<0.0001)
  • In HAE Type 1 or 2, attack rate reduced by 87% vs placebo
  • 45% of deucrictibant-treated participants were attack-free over the entire 24-week treatment period
  • 98%, 96% and 65% achieved at least 50%, 70% and 90% reductions in attack rate vs pre-treatment
  • No treatment-related serious adverse events, no treatment-related cardiovascular adverse events reported
  • Deucrictibant has orphan drug designation from FDA, European Commission, and Swissmedic
  • Phase 2 OLE showed 92.4% average reduction in attack rate over up to ~34 months

Financial Impact

Positive Phase 3 data for a late-stage biotech's primary asset; market cap $2.4B; deucrictibant is the only pipeline drug

revenuemarket cap

Risk Factors

  • Regulatory approval is not guaranteed; FDA may require additional data or raise concerns
  • Competition from existing injectable prophylactics and emerging oral therapies
  • Commercial execution risk as a late-stage biotech transitioning to commercial stage

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3401883

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Viewing Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026